Simulations Plus Azione

Simulations Plus Conversione FCF

Il Tasso di Conversione FCF (FCF/EBITDA) di Simulations Plus (SLP) al 14 ago 2026 è -26,91 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 128,13 % — una variazione del -121,00% (inferiore).

Conversione FCF

-26,91 %

YoY

-121,00%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Simulations Plus ammonta a 2026 -26,91 % . Tasso di Conversione FCF (FCF/EBITDA) di Simulations Plus ammontava a 2025 128,13 % . Diminuisce del -121,00% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Simulations Plus Analisi delle Azioni

Cosa fa Simulations Plus? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Simulations Plus azioni

Tasso di Conversione FCF (FCF/EBITDA) di Simulations Plus è -26,91 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di Simulations Plus è passato da 128,13 % a -26,91 %, con una variazione del -121,00 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Simulations Plus di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Simulations Plus di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — Simulations Plus

Tutte le Metriche Finanziarie — Simulations Plus